Researchers leading the largest genomic
tumor profiling effort of its kind say such studies are technically feasible in a broad population of
adult and pediatric patients with many different types of cancer, and that some patients can benefit by receiving precision drugs targeted to their
tumors» mutations or being enrolled in clinical trials.